Equities research analysts predict that Recro Pharma, Inc. (NASDAQ:REPH) will post earnings of ($0.75) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Recro Pharma’s earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.70). Recro Pharma reported earnings of ($0.50) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 50%. The business is scheduled to issue its next earnings report on Thursday, November 9th.

According to Zacks, analysts expect that Recro Pharma will report full-year earnings of ($2.35) per share for the current financial year, with EPS estimates ranging from ($2.52) to ($2.26). For the next year, analysts forecast that the firm will post earnings of ($2.59) per share, with EPS estimates ranging from ($3.25) to ($2.05). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Recro Pharma.

Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.06. The company had revenue of $16.93 million for the quarter, compared to the consensus estimate of $14.90 million. Recro Pharma had a negative net margin of 46.75% and a negative return on equity of 56.04%.

REPH has been the subject of a number of recent analyst reports. Janney Montgomery Scott cut shares of Recro Pharma from a “buy” rating to a “fair value” rating and dropped their price target for the company from $21.00 to $6.50 in a research report on Wednesday, June 14th. Zacks Investment Research lowered shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Piper Jaffray Companies set a $11.00 price objective on shares of Recro Pharma and gave the stock a “buy” rating in a report on Tuesday, July 25th. Finally, Roth Capital set a $20.00 price objective on shares of Recro Pharma and gave the stock a “buy” rating in a research report on Monday, July 31st. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $13.82.

Shares of Recro Pharma (REPH) traded up 2.7528% during trading on Friday, reaching $9.2272. 70,033 shares of the company’s stock were exchanged. The stock’s market cap is $175.86 million. The company has a 50 day moving average of $7.50 and a 200 day moving average of $7.61. Recro Pharma has a 12-month low of $5.81 and a 12-month high of $10.17.

TRADEMARK VIOLATION NOTICE: “-$0.75 EPS Expected for Recro Pharma, Inc. (REPH) This Quarter” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/0-75-eps-expected-for-recro-pharma-inc-reph-this-quarter/1603490.html.

A number of hedge funds and other institutional investors have recently modified their holdings of REPH. Rothschild Investment Corp IL acquired a new stake in Recro Pharma in the 2nd quarter valued at about $141,000. Wells Fargo & Company MN grew its position in shares of Recro Pharma by 3.0% during the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock worth $150,000 after buying an additional 500 shares in the last quarter. Janney Montgomery Scott LLC grew its position in shares of Recro Pharma by 76.9% during the second quarter. Janney Montgomery Scott LLC now owns 22,085 shares of the specialty pharmaceutical company’s stock worth $155,000 after buying an additional 9,600 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Recro Pharma during the first quarter worth about $156,000. Finally, Teachers Advisors LLC acquired a new position in shares of Recro Pharma during the second quarter worth about $162,000. Institutional investors own 65.06% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.